<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755169</url>
  </required_header>
  <id_info>
    <org_study_id>KiCK Pain</org_study_id>
    <nct_id>NCT01755169</nct_id>
  </id_info>
  <brief_title>Ketamine in Chronic Kid's (KiCK) Pain</brief_title>
  <acronym>KiCK Pain</acronym>
  <official_title>Ketamine in Chronic Kid's (KiCK) Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to select the most tolerable dose of oral ketamine for children with
      chronic pain. Children will be given either placebo or one of three dosages of oral ketamine
      for 2 weeks. The dosage that is most tolerable will be selected for further study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with chronic pain are randomized to one of four arms (three study drug arms, one
      placebo arm) in a randomized, double-blinded fashion. Children are treated for 2 weeks and
      then monitored for an additional 12 weeks. Study participation is a total of 14 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to enroll sufficient patients
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicity</measure>
    <time_frame>2 weeks</time_frame>
    <description>A total of 7 patients enrolled on the trial. However, 2 participants withdrew from the trial before they were randomized and 1 participant withdrew from the trial before being treated. Hence, the total number of patients for assessment is 4.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Ketamine 0.25 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.5 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 1 mg/kg/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
    <arm_group_label>Ketamine 0.25 mg/kg/dose</arm_group_label>
    <arm_group_label>Ketamine 0.5 mg/kg/dose</arm_group_label>
    <arm_group_label>Ketamine 1 mg/kg/dose</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject, parent, or guardian willing and able to give informed consent

          -  NRS for pain over the past 24 hours &gt;4 at baseline

          -  Chronic pain, which has been present for &gt;3 months, or persisting longer than is
             normal for the underlying diagnosis

          -  Chronic pain related to physiologic diagnoses including but not limited to: cancer,
             rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and
             neuromuscular disease (e.g. Duchenne muscular dystrophy)

          -  Able to tolerate and cooperate with neurocognitive assessment

          -  Age 8-20 years old

        Exclusion Criteria:

          -  If they are known or suspected to have drug addiction

          -  Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar
             disorder

          -  Uncontrolled hypertension

          -  Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of
             normal.

          -  Previous intolerance or allergic reaction to ketamine

          -  Pregnancy

          -  Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug
             administration or within 5 half-lives of the respective medication, whichever is
             longer, until study conclusion.

          -  Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study
             drug administration until study conclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy-Lee Bredlau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <results_first_submitted>November 28, 2016</results_first_submitted>
  <results_first_submitted_qc>November 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2017</results_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Amy-Lee Bredlau</investigator_full_name>
    <investigator_title>Director, Pediatric Brain Tumor Program</investigator_title>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Child</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only aggregate data will be shared.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 7 patients enrolled on the trial. However, 2 participants withdrew from the trial before they were randomized and 1 participant withdrew from the trial before being treated. Hence, the total number of patients for assessment is 4.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine 0.25 mg/kg/Dose</title>
          <description>A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="P2">
          <title>Ketamine 0.5 mg/kg/Dose</title>
          <description>A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="P3">
          <title>Ketamine 1 mg/kg/Dose</title>
          <description>A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine 0.25 mg/kg/Dose</title>
          <description>A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="B2">
          <title>Ketamine 0.5 mg/kg/Dose</title>
          <description>A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="B3">
          <title>Ketamine 1 mg/kg/Dose</title>
          <description>A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>8-20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicity</title>
        <description>A total of 7 patients enrolled on the trial. However, 2 participants withdrew from the trial before they were randomized and 1 participant withdrew from the trial before being treated. Hence, the total number of patients for assessment is 4.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.25 mg/kg/Dose</title>
            <description>A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.5 mg/kg/Dose</title>
            <description>A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
          </group>
          <group group_id="O3">
            <title>Ketamine 1 mg/kg/Dose</title>
            <description>A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicity</title>
          <description>A total of 7 patients enrolled on the trial. However, 2 participants withdrew from the trial before they were randomized and 1 participant withdrew from the trial before being treated. Hence, the total number of patients for assessment is 4.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine 0.25 mg/kg/Dose</title>
          <description>A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="E2">
          <title>Ketamine 0.5 mg/kg/Dose</title>
          <description>A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="E3">
          <title>Ketamine 1 mg/kg/Dose</title>
          <description>A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Amy-Lee Bredlau</name_or_title>
      <organization>MUSC</organization>
      <phone>843-876-0444</phone>
      <email>bredlau@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

